⌘K
t
Scancell Holdings plc granted share options to its Executive Directors: Phil L'Huillier (CEO), Lindy Durrant (CSO), and Sath Nirmalananthan (CFO). On 19 February 2025, these options were granted with an exercise price of 11.7 pence each, vesting over three years from the grant date and expiring on 19 February 2035. The grants comprised 31,103,440 options for Phil L'Huillier, 5,183,907 for Lindy Durrant, and 1,000,000 for Sath Nirmalananthan, bringing their total option holdings to 3.00%, 2.70%, and 0.19% of the current issued share capital, respectively.
| Date | 20 Feb 2025 |
| Time | 07:00:09 |
| Category | Director/PDMR dealings |
| ID | 7667X |
Scancell Holdings plc
("Scancell" or the "Company")
Issue of share options
Scancell Holdings plc (AIM: SCLP), a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, announces that on 19 February 2025, share options to acquire ordinary shares of 0.1 pence each in the capital of the Company (the "Options") were granted to Phil L'Huillier, CEO and Executive Director, Lindy Durrant, CSO and Executive Director and Sath Nirmalananthan, CFO and Executive Director (the "Executive Directors").
The Options have been granted as follows:
|
Director |
Existing options over Ordinary Shares |
Number of Options granted |
Total options held following grant |
% of current issued share capital |
|
Phil L'Huillier |
0 |
31,103,440 |
31,103,440 |
3.00% |
|
Lindy Durrant |
22,850,000 |
5,183,907 |
28,033,907 |
2.70% |
|
Sath Nirmalananthan |
1,000,000 |
1,000,000 |
2,000,000 |
0.19% |
The Options have been granted pursuant to the Company's long term incentive plan, have an exercise price of 11.7 pence each, the 3 month volume weighted average price on the grant date, and will vest over three years in three equal tranches from 19 February 2025 with no vesting criteria other than to remain in employment. Any unexercised Options which are being granted per the above will expire at 6pm on 19 February 2035.
The Board of Scancell approved the issuance of the Options to incentivise and retain directors and staff of the Company. The Board considered both historical practices and on-going funding requirements in this regard.
Related Party Transaction
The issue of Options to the Executive Directors are deemed to be a related party transaction pursuant to AIM Rule 13 of the AIM Rules for Companies. The Company's directors who are independent of the related party transaction, being all the directors other than the Executive Directors, consider, having consulted with the Company's Nominated Adviser, Panmure Liberum Limited, that the terms of the related party transactions are fair and reasonable insofar as the shareholders of the Company are concerned.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Phil L'Huillier |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Chief Executive Officer and PDMR |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Scancell Holdings plc |
|
b) |
LEI |
2138008RXEG856SNP666 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument |
Options to acquire ordinary shares |
|
b) |
Identification Code |
GB00B63D3314 |
|
c) |
Nature of the transaction |
Grant of options to acquire ordinary shares |
|
|
|
|
|
d) |
Price(s) and volume(s) |
31,103,440 share options 11.7 pence per share option |
|
e) |
Aggregated information - Aggregated volume - Price |
N/A (single transaction)
|
|
f) |
Date of the transaction |
19 February 2025 |
|
g) |
Place of the transaction |
Outside a trading venue |
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Lindy Durrant |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Chief Scientific Officer and PDMR |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Scancell Holdings plc |
|
b) |
LEI |
2138008RXEG856SNP666 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument |
Options to acquire ordinary shares |
|
b) |
Identification Code |
GB00B63D3314 |
|
c) |
Nature of the transaction |
Grant of options to acquire ordinary shares |
|
|
|
|
|
d) |
Price(s) and volume(s) |
5,183,907 share options 11.7 pence per share option |
|
e) |
Aggregated information - Aggregated volume - Price |
N/A (single transaction)
|
|
f) |
Date of the transaction |
19 February 2025 |
|
g) |
Place of the transaction |
Outside a trading venue |
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Sath Nirmalananthan |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Chief Financial Officer and PDMR |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Scancell Holdings plc |
|
b) |
LEI |
2138008RXEG856SNP666 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument |
Options to acquire ordinary shares |
|
b) |
Identification Code |
GB00B63D3314 |
|
c) |
Nature of the transaction |
Grant of options to acquire ordinary shares |
|
|
|
|
|
d) |
Price(s) and volume(s) |
1,000,000 share options 11.7 pence per share option |
|
e) |
Aggregated information - Aggregated volume - Price |
N/A (single transaction)
|
|
f) |
Date of the transaction |
19 February 2025 |
|
g) |
Place of the transaction |
Outside a trading venue |
-ENDS-
For further information, please contact:
Scancell Holdings plc +44 (0) 20 3709 5700
Phil L'Huillier, CEO
Sath Nirmalananthan, CFO
Professor Lindy Durrant, CSO
Dr Jean-Michel Cosséry, Non-Executive Chairman
Panmure Liberum Limited (Nominated Advisor and Joint Broker) +44 (0) 20 7886 2500
Emma Earl/ Will Goode/ Mark Rogers (Corporate Finance)
Rupert Dearden (Corporate Broking)
WG Partners LLP (Joint Broker) +44 (0) 20 3705 9330
David Wilson/ Claes Spang/ Satheesh Nadarajah/ Erland Sternby
ICR Healthcare +44 (0) 20 37095700
Mary-Jane Elliott/ Angela Gray/ Stephanie Cuthbert [email protected]
About Scancell
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies. Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody® ) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab® ) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab® ).
For further information about Scancell, please visit: https://www.scancell.co.uk/